dihydroergotoxine and Arterial-Occlusive-Diseases

Topics: Arterial Occlusive Diseases; Cardiovascular Agents; Cinnarizine; Clinical Trials as Topic; Dihydroergotamine; Dihydroergotoxine; Drug Combinations; Exercise Test; Flunarizine; Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Placebos; Pyrrolidines; Secologanin Tryptamine Alkaloids; Yohimbine

The therapeutical effect and tolerance of Defluina was studied in a selective open trial of 24 patients suffering from peripheral arterial diseases in Fontaine's stage I and II. All patients were treated with Defluina, 30 drops three times a day during a period of six weeks. From the statistically significant improvement of the different control parameters it can be concluded that peripheral arterial circulation has increased considerably in the course of the Defluina treatment. The preparation was always well tolerated, no side-effects were observed.

Topics: Aged; Arterial Occlusive Diseases; Clinical Trials as Topic; Dihydroergotamine; Dihydroergotoxine; Drug Combinations; Drug Evaluation; Female; Humans; Male; Middle Aged; Vasodilator Agents; Yohimbine

Effectiveness and tolerance of Defluina was studied in a selective open trial including 30 patients (17 males, 13 females, mean age 70 years) suffering from peripheral arterial occlusive diseases of different stages. All patients were treated with Defluina, 20 drops thrice a day during a mean period of 30 days. Simultaneous application of further peripheral vasodilators was excluded. Subjective and objective parameters (pulse, Ratschow's test, walking distance) of 27 patients (15 males, 12 females) were evaluated. After 4 weeks of therapy an improvement of all parameters especially of the walking distance was observed. Within 4 weeks 3 of 5 ulcera cruris as well as an initially existing gangrene were closed. Deflunia was well tolerated by 25 patients, very well tolerated by 2. The therapy was discontinued in 3 patients: 2 because of unchanged complaints after 13 and 20 days of therapy, 1 after 17 days due to dull gastric pain following intake of the drug. Cardiac side-effects or steal phenomena were not observed.

Topics: Aged; Arterial Occlusive Diseases; Clinical Trials as Topic; Dihydroergotamine; Dihydroergotoxine; Drug Combinations; Drug Evaluation; Ergoloid Mesylates; Ergotamines; Female; Hemodynamics; Humans; Male; Middle Aged; Yohimbine

Topics: Aged; Arterial Occlusive Diseases; Cerebrovascular Disorders; Cyclandelate; Dihydroergotoxine; Female; Humans; Isoxsuprine; Leg; Male; Vasodilator Agents

Topics: Aged; Arterial Occlusive Diseases; Dihydroergotoxine; Drug Evaluation; Female; Humans; Male; Middle Aged

The therapeutical effect of Defluina was studied in a selective open trial of 50 patients suffering from peripheral arterial occlusive diseases of different stages. All patients were treated with Defluina, 30 drops three times a day during a period of six weeks. Control parameters of 46 patients (18 males, 26 females, mean age of 59.8 +/- 1.7 years) were evaluated. After therapy a significant improvement of all applied parameters was observed. The positive effect of the Defluina-medication on the initial--partly severe--varicose ulcera, with gangrenous alterations, has to be pointed out. After 6 weeks the varicose ulcera were partly closed, at least they showed fresh granulations. During therapy no adverse reactions were registered. All patients estimated Defluina as very well tolerable. The therapeutic effect of Defluina on the carefully investigated group of 46 patients could be estimated in 38 cases with excellent/good, in 7 cases with good/moderate and only in 1 case with moderate.

Topics: Adult; Aged; Arterial Occlusive Diseases; Diabetes Complications; Dihydroergotamine; Dihydroergotoxine; Drug Combinations; Drug Evaluation; Ergotamines; Female; Gangrene; Humans; Intermittent Claudication; Leg Ulcer; Male; Middle Aged; Pulse; Yohimbine

Topics: Adult; Arterial Occlusive Diseases; Dihydroergotamine; Dihydroergotoxine; Drug Combinations; Drug Evaluation; Female; Humans; Male; Raynaud Disease; Secologanin Tryptamine Alkaloids; Vasodilator Agents

The alpha-adrenergic blocking drugs, phentolamine and Hydergine, both act centrally at different sites to depress and enhance the pressor and sympathetic nerve response to decreased baroreceptor afferent input in anesthetized cats. Depression of the rise in blood pressure and sympathetic nerve discharge during bilateral carotid occlusion (BCO) followed injection of the agents into the 4th cerebral ventricle when the brain was intact but not when connections were interrupted at the midcollicular level by transection or lesion. Enhancement of responses occurred when drug distribution was confined to the brain rostral to the midcollicular level via injection into the 3rd cerebral ventricle with the cerebral aqueduct cannulated. Both agents decreased resting blood pressure and Hydergine decreased heart rate in intact and decerebrate preparations but not in 3rd ventricle-cerebral aqueduct experiments. We found that pretreatment with the noradrenergic precursor. L-dopa consistently prevented depression by phentolamine but was less effective against Hydergine. The results indicate that mechanisms which enhance and suppress the baroreceptor pressor response are normally operative in anesthetized cats and, furthermore, that neural pathways mediating the effects are ones connecting the caudal brainstem with supracollicular levels of the brain. It is further suggested that the pathways may be noradrenergic.

Topics: Animals; Arterial Occlusive Diseases; Bradycardia; Carotid Artery Diseases; Cats; Decerebrate State; Depression, Chemical; Dihydroergotoxine; Dose-Response Relationship, Drug; Hemodynamics; Injections, Intraventricular; Levodopa; Norepinephrine; Phentolamine; Phenylephrine; Pressoreceptors; Stimulation, Chemical; Superior Colliculi; Sympathetic Nervous System

Topics: Adult; Arterial Occlusive Diseases; Cerebrovascular Disorders; Dihydroergotamine; Dihydroergotoxine; Drug Combinations; Ergoloid Mesylates; Ergotamines; Extremities; Humans; Male; Middle Aged; Secologanin Tryptamine Alkaloids